Zylox-Tonbridge Medical Technology Co., Ltd. 02190.HKの前四半期の収益はどうでしたか?
Zylox-Tonbridge Medical Technology Co., Ltd.の収益見積もりはいくらですか?
Zylox-Tonbridge Medical Technology Co., Ltd.の収益品質スコアはどれくらいですか?
Zylox-Tonbridge Medical Technology Co., Ltd.はいつ収益を報告しますか?
Zylox-Tonbridge Medical Technology Co., Ltd.の予想収益はいくらですか?
Zylox-Tonbridge Medical Technology Co., Ltd.は収益予想を上回りましたか?
主要データ
前終値
$25.94
始値
$25.92
当日レンジ
$25.54 - $26.4
52週レンジ
$10.56 - $28
取引高
346.5K
平均取引高
662.4K
1株当たり利益(TTM)
0.52
配当利回り
--
時価総額
$8.3B
ZYLOXTBとは何ですか?
Zylox-Tonbridge Medical Technology Co., Ltd. engages in the production and sales of neurovascular and peripheral-vascular interventional surgical devices. The company is headquartered in Hangzhou, Zhejiang and currently employs 875 full-time employees. The company went IPO on 2021-07-05. The neurovascular interventional devices primarily include SilverSnake Intracranial Support Catheter, Phoenix Neurovascular Embolization Coil, Tonbridge Kylin Flow Diverter, Thrombite Clot Retriever Device and Beidou SS Neurovascular Guidewire. The peripheral vascular interventional devices primarily include UltraFree Drug Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, ZYLOX Octoplus Retrievable Inferior Vena Cava Filter, Snare Retrieval Kit for Inferior Vena Cava Filter and ZYLOX Swan Endovenous Radiofrequency Ablation Catheter. The firm primarily operates its businesses in the domestic market and overseas markets, including Germany, France, Italy, and Turkiye.